Pharmaceutical Safety Review • Moderate Interaction Classification

Triglyceride Omega-3 vs Ethyl Ester vs Krill Oil Prescription Drug Interactions & CYP450 Profile

Systematic analysis of cytochrome P450 enzyme metabolism, renal clearance competition, and clinical contraindications.

Absolute Clinical Contraindications

  • Concurrent high-dose antithrombotic or anticoagulant therapy without INR monitoring
  • Fish or shellfish allergy (for krill)
  • Upcoming scheduled major surgery

Reported Clinical Adverse Events

  • Fishy burps or reflux (sign of high oxidation or EE formulation)
  • Mild loose stools at >4g doses
  • Increased bleeding time

Hepatic Cytochrome P450 (CYP) & Transporter Pathways

Compounds that modulate CYP3A4, CYP2D6, or P-glycoprotein (P-gp) can alter the bioavailability of concurrent medications including statins, anticoagulants, immunosuppressants, and blood pressure therapies:

  • CYP3A4 Substrate / Inhibitor: Potential competition with oral medications metabolized through hepatic CYP3A4 pathways.
  • Gastrointestinal Transit Modulation: GLP-1 receptor agonists and delayed-release botanicals slow gastric emptying, which may delay Tmax for orally administered therapeutics.
  • Pharmacokinetic Half-Life Clearance: Systemic clearance requires approximately 5 elimination half-lives (RBC membrane incorporation half-life: 4 - 8 weeks).

Protocol Audit Links for Triglyceride Omega-3 vs Ethyl Ester vs Krill Oil

← Return to Triglyceride Omega-3 vs Ethyl Ester vs Krill Oil Monograph Calculate Weight Dosage Table → Launch Full Multi-Drug Interaction Checker →